26
|
Hamidieh AA, Hamidi Z, Nedaeifard L, Heshmat R, Haralambous H, Alimoghaddam K, Larijani B, Ghavamzadeh A, Mohajeri-Tehrani MR. Bone mineral density in ex-thalassemic pediatric patients. Hematol Oncol Stem Cell Ther 2012; 5:70-1. [PMID: 22446616 DOI: 10.5144/1658-3876.2012.71] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
27
|
Bashash D, Ghaffari SH, Zaker F, Hezave K, Kazerani M, Ghavamzadeh A, Alimoghaddam K, Mosavi SA, Gharehbaghian A, Vossough P. Direct short-term cytotoxic effects of BIBR 1532 on acute promyelocytic leukemia cells through induction of p21 coupled with downregulation of c-Myc and hTERT transcription. Cancer Invest 2012; 30:57-64. [PMID: 22236190 DOI: 10.3109/07357907.2011.629378] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Acute promyelocytic leukemia (APL) is characterized by specific t(15;17), distinct morphologic picture, and clinical coagulopathy that contribute to the morbidity and mortality of the disease. This study aims to investigate the effects of antitelomerase compound BIBR1532 on APL cells (NB4). BIBR 1532 exerts a direct short-term growth suppressive effect in a concentration-dependent manner probably through downregulation of c-Myc and hTERT expression. Our results also suggest that induction of p21 and subsequent disturbance of Bax/Bcl-2 balanced ratio as well as decreased telomerase activity may be rational mechanisms for the potent/direct short-term cytotoxicity of high doses of BIBR1532 against NB4 cells.
Collapse
|
28
|
Hamidieh A, Behfar M, Hamdi A, Ostadali M, Jalili M, Jalali A, Hosseini A, Basirpanah S, Ghavamzadeh A. Hematopoietic Stem Cell Transplantation for Pediatric Patients with Hereditary Bone Marrow Failure Syndromes Without Total Body Irradiation. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
29
|
Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi S, Bahar B, Iravani M, Ghaffari F, Jalili M, Jalali A. Autologous and Allogenic Stem Cell Transplantation Results in Multiple Myeloma Patients – Single Center Study. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Hamidieh A, Beigi D, Fallahi B, Behfar M, Jalili M, Hamdi A, Hosseini A, Ghavamzadeh A. Comparison of Autologous Hematopoietic Stem Cell Transplantation with and Without Metaiodobenzylguanidine (MIBG) in Patients with High Risk Neuroblastoma. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.138] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Hamidieh A, Mohajeri-Tehrani M, Mirboluk M, Hamdi A, Behfar M, Jalili M, Shamshiri A, Ghavamzadeh A. Bone Mineral Density Changes in Patients with β-Thalassemia Major After Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
32
|
Ghavamzadeh A, Hoghooghi M, Jahani M, Alimoghaddam K, Mousavi S, Bahar B, Iravani M, Jalili M, Jalali A. Effect of Pre-Transplant Chemotherapy Before Human Leukocyte Antigen Identical Sibling Transplantation for Acute Myelogenous Leukemia in First Complete Remission. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Hamidieh AA, Pourpak Z, Hosseinzadeh M, Fazlollahi MR, Alimoghaddam K, Movahedi M, Hosseini A, Chavoshzadeh Z, Jalili M, Arshi S, Moin M, Ghavamzadeh A. Reduced-intensity conditioning hematopoietic SCT for pediatric patients with LAD-1: clinical efficacy and importance of chimerism. Bone Marrow Transplant 2011; 47:646-50. [DOI: 10.1038/bmt.2011.140] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
34
|
Saddadi F, Najafi I, Hakemi M, Jahani M, Ali Moghadam K, Ghavamzadeh A, Soleimanian T, Perkowska-Ptasinska A, Wagrowska-Danilewicz M, Danilewicz M, Halon A, Komuda E, Karkoszka H, Andrzejewska A, Okon K, Kurnatowska I, Krasnicka M, Hryszko T, Kusztal M, Wiechecka-Korenkiewicz J, Marcinkowska E, Korenkiewicz J, Marszalek A, Sypniewska G, Manitius J, Cappuccino L, Verzola D, Tosetti F, Marre S, Villaggio B, Salvidio G, Garibotto G, Pasquariello A, Innocenti M, Pasquariello G, Mattei P, Samoni S, Sami N, Cupisti A, Malvar B, Viana H, Galvao M, Carvalho F, Oksa A, Demes M, Danis D, Hilhorst M, van Paassen P, van Breda Vriesman P, Cohen Tervaert JW, Perkowska-Ptasinska A, Ciszek M, Urbanowicz A, Kwiatkowski A, Durlik M, Saito T, Kawano M, Saeki T, Nishi S, Yamaguchi Y, Hisano S, Nakashima H, Yamanaka N, Oh SW, Chin HJ, Na KY, Chae DW, Ozkan G, Ulusoy S, Ersoz S, Orem A, Alkanat M, Yucesan F, Kaynar K, Al S, Simic Ogrziovic S, Bojic S, Basta Jovanovic G, Kotur Stevuljevic J, Dosaj V, Lezaic V, Yagisawa T, Kimura T, Ishikawa N, Yashi M. Renal histopathology. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
35
|
Ghavamzadeh A, Alimoghaddam K, Hamidieh A, Jalili M, Bahar B, Iravani M, Mousavi S, Jahani M. Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Severe Aplastic Anemia. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
36
|
Hamidieh A, Ostadali M, Jalili M, Behfar M, Basirpanah S, Houseini A, Bakhti O, Ghavamzadeh A. Allogeneic Stem Cell Transplantation From Donors Other Than HLA-Matched Siblings in Pediatric Patients: Family Bank. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Alimoghaddam K, Jahani M, Mousavi S, Bahar B, Iravani M, Hamidieh A, Jorjani H, Jalali A, Ghavamzadeh A. Hematopoietic Stem Cell Transplantation in Lymphoma Patients: the Iranian Experience. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.300] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Hamidieh A, Moeininia F, Alimoghaddam K, Jalili M, Shamshiri A, Ghavamzadeh A. Evaluation of Myocardial and Hepatic T2∗ MRI Changes in β-Thalassemia Major Hematopoietic Stem Cell Transplantation Recipients and the Effect of Iron Overload Therapy. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Hadjibabaie M, Rahimian S, Jahangard-Rafsanjani Z, Amini M, Alimoghaddam K, Iravani M, Ghavamzadeh A, Sadrai S. Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation. Daru 2011; 19:216-23. [PMID: 22615660 PMCID: PMC3232103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2011] [Revised: 06/20/2011] [Accepted: 06/22/2011] [Indexed: 10/27/2022] Open
Abstract
BACKGROUND AND THE PURPOSE OF THE STUDY Many factors have been reported that contribute to the wide intra- and inter-patient variability of Busulfan (Bu) disposition. The purpose of this study was to develop a population pharmacokinetic model and to determine the covariates affecting the pharmacokinetics (PK) of Bu in Iranian adult patients who received oral high-dose as a conditioning regimen before Hematopoietic Stem Cell Transplantation (HSCT). METHODS A population PK analysis was performed in 30 patients who received an oral Bu and cyclophosphamide regimen before HSCT. Bu was given orally according to the protocol of the institution. In order to prevent seizures caused by Bu, phenytoin was administered orally one hour before each dose of Bu.A total of 180 blood samples were analyzed by HPLC and PK parameters were estimated by the non-linear mixed effect model by MONOLIX 3.1 program. A one-compartment model with an additive error model was used to describe the concentration-time profile of Bu. RESULTS Patients' disease and weight was found to be the determinant factors for clearance (CL) and the volume of distribution (Vd) according to Monolix analysis. The covariate entered in final model followed by these equations:[Formula: see text][Formula: see text] In this limited study, the age (15-43 years) had no significant effect. For a patient weighting 60 kg, the typical CL and Vd were estimated to be 13.4 l/hr and 42.6 L, respectively. The interindividual variability of CL and Vd were 13.6 and 6.3%, respectively. There was no significant metabolic induction in these four days as is evident by comparing the trough levels of Bu. However it should be mentioned that, one tailed t-test p-values of the days of two and three, two and four and three and four were 0.083, 0.069 and 0.388, respectively. MAJOR CONCLUSIONS Results of this study showed that the type of disease was a determinant of CL and the weight of patient was a determinant of Vd for Bu population PK parameters. A reliable PK parameters and Css, estimated from only one plasma concentrations (5 hrs after the first dose), were validated. Since these methods require few sampling and are easy to be used, the limited sampling methods might be advantageous in the routine clinical practice.
Collapse
|
40
|
Dardaei L, Shahsavani R, Ghavamzadeh A, Behmanesh M, Aslankoohi E, Alimoghaddam K, Ghaffari SH. The detection of disseminated tumor cells in bone marrow and peripheral blood of gastric cancer patients by multimarker (CEA, CK20, TFF1 and MUC2) quantitative real-time PCR. Clin Biochem 2010; 44:325-30. [PMID: 21130081 DOI: 10.1016/j.clinbiochem.2010.11.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2010] [Revised: 11/01/2010] [Accepted: 11/20/2010] [Indexed: 12/16/2022]
Abstract
OBJECTIVE To investigate the suitability of multimarker detection of DTCs in PB and BM of GC patients. DESIGN AND METHOD A qRT-PCR assay was developed to estimate the number of CEA, CK20, TFF1 and MUC2 transcripts in PB and BM samples of 35 GC patients prior to the initiation of therapy. PB samples from healthy volunteers and BM from patients with hematological malignancies were used as negative controls. RESULTS In PB analysis; 22.9%, 37.1%, 31.4%, and 22.9% of GC patients and in BM analysis; 20%, 28.6%, 45.7%, and 22.9% of GC patients were positive for CEA, CK20, TFF1 and MUC2 mRNAs, respectively. Samples from the control group were negative for the expression of all the markers tested in this study. A higher positive ratio was obtained with the multimarker detection in comparison to the single marker detection. There was a significant correlation between the PB and BM samples for DTC detection. CONCLUSION Multimarker detection assay is a reliable and powerful tool for the early detection of DTCs in GC patients.
Collapse
|
41
|
Ghavamzadeh A, Alimoghaddam K, Ghaffari S, Rostami S, Jahani M, Iravani M, Mousavi S, Jalili M, Alizadeh N, Khodabandeh A. Results of new cases of APL treatment by arsenic trioxide and long-term follow-up: Is it time for using arsenic trioxide in first-line treatment? J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Mandegary A, Hosseini R, Ghaffari SH, Alimoghaddam K, Rostami S, Ghavamzadeh A, Ghahremani MH. The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide. Ann Oncol 2010; 21:1884-1890. [PMID: 20164150 DOI: 10.1093/annonc/mdq034] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Promising reports exist regarding the use of arsenic trioxide (ATO) as first-line treatment in acute promyelocytic leukemia (APL). Although the in vitro effect of ATO is extensively studied, the in vivo mechanism(s) of ATO action is mostly unknown. PATIENTS AND METHODS Newly diagnosed APL patients were involved and received ATO (0.15 mg.kg/day) for 28 days as induction followed by consolidation therapy. Bone marrow (BM) aspirates were obtained on days 0, 14 and 28 of treatment for further molecular studies. Clinical findings and white blood cell counts were recorded as well. RESULTS Complete remission was observed in 17 (85%) patients with the median duration of 28 days (18-38) and cumulative dosage of median 280 mg (180-350). Hyperleukocytosis and APL differentiation syndrome (63%), gastrointestinal disorders (30%), liver enzyme elevation and night sweating (50%) were the most prevalent side-effects. The expression of Bax, ERK1 and p38 proteins and caspase-3 activity increased significantly in promyelocytes of BM aspirates at days 14 and 28 of induction therapy. CONCLUSION(S) These findings point toward the role of p38 and Bax in the induction of apoptosis, which was confirmed by increase in caspase-3 activity. However, the increase in ERK1 expression with regard to leukocytosis could translate to a proliferative/differentiation effect.
Collapse
|
43
|
Ghavamzadeh A, Alimoghaddam K, Hamidieh A, Karimi A, Bashtar M, Shamshiri A. Co-Transplantation Of HLA-matched Related Donors Culture-Expanded Mesenchymal Stromal Cells And Hematopoietic Stem Cells In Thalassemia Major Patients. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.183] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Ghavamzadeh A, Alimoghaddam K, Jahani M, Hamidieh A, Mousavi S, Khatami F, Jalali A, Alimohammadi A. Hematopoietic Stem Cell Transplantation For Major Thalassemia: Nineteen Years Experience In Iran. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
45
|
Hamidieh A, Pourpak Z, Alimoghaddam K, Fazlollahi M, Jalili M, Movahedi M, Moin M, Ghavamzadeh A. Fludarabine-Based Reduced Intensity Conditioning Regimens For Hematopoietic Stem Cell Transplantation In Pediatric Patients With Primary Immunodeficiency. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
46
|
Ghavamzadeh A, Hamidieh A, Jahani M, Alimoghaddam K, Iravani M, Mousavi S, Bahar B, Khodabandeh A, Jalili M. HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation In 36 Pediatric Patients With Severe Acquired Aplastic Anaemia. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
47
|
Malekzadeh R, Mohamadnejad M, Alimoghaddam K, Bagheri M, Baharvand H, Ghavamzadeh A. Cell-based regenerative therapy as an alternative to liver transplantation for end-stage liver disease: experience from iran. Int J Organ Transplant Med 2010; 1:21-7. [PMID: 25013559 PMCID: PMC4089219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2009] [Accepted: 06/24/2009] [Indexed: 11/03/2022] Open
Abstract
Several types of cells including mature hepatocytes, adult liver progenitor cells and human embryonic stem cells, fetal liver progenitor cells, bone marrow derived hematopoietic or mesenchymal stem cells, and umbilical cord blood cells-both in rodents and humans-have been reported to be capable of self-replication, giving rise to daughter hepatocytes, both in vivo and in vitro. They have been shown to be able to repopulate liver in both animal models of liver injury and in patients with liver disease and to improve liver function. Human embryonic stem cell therapy seems to be a great promise for the treatment of liver cirrhosis, but there is no human clinical application due to ethical concerns or difficulties in harvesting or safely and efficiently expanding sufficient quantities. In contrast, adult bone marrow-derived hematopoietic or mesenchymal stem cells, which can be easily and safely harvested, have been used in clinical trials to treat several chronic diseases including chronic liver disease. Cell therapy offers exciting promise for future treatment of cirrhosis and metabolic liver diseases, but significant technical hurdles remain that will only be overcome through years of intensive research. There is also serious concern about the long-term safety of stem cell therapy and the possibility of tumor development. Herein, we present our experience with cell therapy in treatment of chronic liver disease in Iran.
Collapse
|
48
|
Momeny M, Zakidizaji M, Ghasemi R, Mirzaeekhalilabadi R, Mardanivalandani H, Ghavamzadeh A, Alimoghaddam K, Ghaffari S. 9241 Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71932-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
49
|
Ghavamzadeh A, Hashemi S, Alimoghaddam K, Nasri Moghaddam Z, Shadpour M, Jalili M. Phase II trial of old age acute myeloid leukemia treatment by arsenic trioxide and low-dose subcutaneous cytosin arabinoside. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7075 Background: AML is a disease of old age, but unfortunately due to several factors standard treatment can not be delivered to these patients. Here we tried to achieve to bet possible response to these patients. Methods: Eleven old age patients selected for this trial. Patients couldn't tolerate standard treatment of AML due to old age or comorbid disorders. Treatment consist of best supportive care plus administration of low dose ARA-C (20mg/day as SQ) for 10 days each months and arsenic trioxide 10 mg/day as 2 hour iv infusion each month. Patients followed by CBC and BMA/B when peripheral blood normalized or every other month. Results: This cohort consist of 8 men and 3 women. Median age was 75 y/o (55–80). Median WBC count Hb level and platelet count at presentation were 42,860μl, 8.3g/dl and 30,500/μl, respectively. Complete remission observed in 6 and partial remission in one patient (RR = 63.6%), but remission was short live, after 6 months one patient was in CR and one in PR. After 12 months, only one patient was in PR. Median survival was 6 months and 6 patients survive more than 6 months. Two patients are alive after 12 months. Conclusions: Although prognosis of old age AML remain poor, but with this type of treatment RR is acceptable. In this very high-risk group of very old AML, combination of ATO and ARA-C possibly could improve survival. No significant financial relationships to disclose.
Collapse
|
50
|
Ghavamzadeh A, Alimoghaddam K, Karimi A, Manookian A, Asadi M, Maheri R, Shamshiri A. Outpatient stem cell transplantation for multiple myeloma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19553 Background: The aim of this study was to explore the feasibility and safety of performing aoutologous stem cell transplantation (ASCT) on an outpatient basis. Methods: 142 patients with multiple myeloma (MM) in complete remission (CR) or partial remission (PR) received ASCT on an outpatient or inpatient basis. In the inpatient group 77 patients and in outpatient group 65 patients received 200 or 140 mg/m2 melphalan as conditioning regimen respectively. In outpatient group all the patients were programmed to go home the day after ASCT and to be re-hospitalized in the case of febrile neutropenia or other sever toxicities. We used caregiver, general physician, staff nurse as an outpatient and visit team and also unequipped routine house of the patients during neutropenia. Results: Median age was 50.2 years (ranged 27–68) with 70% male. Median hospital stay were 25 days in inpatient and. 4.8 days in outpatient respectively (p<0.01). There were not significant differences between these groups in aphresis days, granulocyte colony stimulating factor requirement for mobilization and mononuclear cell, There were also significant reduction (p<0.001) in parenteral antibiotic, blood product requirement and need for total parenteral nutrition. The most frequent causes of re-admission (outpatient group) were febrile neutropenia and sever mucositis need TPN. 2 years overall survival rate was 98.2% (SE=2%) in inpatient groups and 86.6% (SE=5.7) in outpatient groups.We did not have any death in first month after transplantatio in outpatient group. Conclusions: We describe an outpatient program based on management of the patient in his/her house during aplastic phase. Our results clearly indicate that such a procedure is feasible and safe in a patient population with a caregiver. No significant financial relationships to disclose.
Collapse
|